Femasys FY23 net loss $14.25M, sales down 11%; FemaSeed FDA clearance and positive trial data

FEMASYS INC

Net loss $14.25M ($0.93/share) vs $11.39M ($0.96/share) in FY22; sales $1.07M (-11% YoY).
FDA cleared FemaSeed for infertility; pivotal trial showed 24% pregnancy rate in severe male factor cohort.
Cash $21.7M expected to fund operations into 2H 2025; convertible notes of $4.26M issued.
Appointed Richard Spector as CCO and James Liu as CMO.
FemBloc permanent birth control trial enrollment initiated.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FEMASYS INC reported year ended December 31, 2023 results: net income Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders.

Period: year ended December 31, 2023
Net income: Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders
Result: reported results

Exact text from the filing

Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2023, compared to net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FEMASYS INC reported year ended December 31, 2022 results: net income net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders.

Period: year ended December 31, 2022
Net income: net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders
Result: reported results

Exact text from the filing

Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2023, compared to net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-24-016160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.